|
|
|
|
| LEADER |
01093nam a2200289 a 4500 |
| 001 |
c000057658 |
| 003 |
CARM |
| 005 |
20010227134740.0 |
| 008 |
721004s1972 xx 000 0 eng d |
| 010 |
|
|
|a 78-185827
|
| 019 |
1 |
|
|a 5098920
|z 88786
|5 LACONCORD2021
|
| 035 |
|
|
|a (OCoLC)482182
|5 LACONCORD2021
|
| 040 |
|
|
|a USNLM
|b eng
|c USNLM
|d VU
|
| 050 |
0 |
0 |
|a RC685.H8
|b G49
|
| 060 |
0 |
0 |
|a WG 340
|b M592 1972
|
| 082 |
0 |
4 |
|a 616.1/32/061
|
| 245 |
0 |
0 |
|a Methyldopa in the management of hypertension.
|b Edited by Ray W. Gifford, Jr.
|
| 260 |
|
|
|a West Point, Pa.
|b Merck Sharp & Dohme,
|c [c1972]
|
| 300 |
|
|
|a 138 p.
|
| 500 |
|
|
|a Direction circulars on MS & D products (44 p.) inserted at end.
|
| 650 |
|
2 |
|a Hypertension
|x Drug therapy.
|
| 650 |
|
2 |
|a Methyldopa
|x therapeutic use.
|
| 700 |
1 |
|
|a Gifford, Ray W.
|q (Ray Wallace),
|d 1923-
|
| 710 |
2 |
|
|a Merck Sharp & Dohme.
|
| 852 |
8 |
|
|b CARM
|h A2:AD30E0
|i C00006
|p 0000004
|f BK
|
| 999 |
f |
f |
|i a655e1ab-074a-5101-871a-2fb7b74e7e4f
|s 6d6a612a-2573-52f2-be9b-d38fd77e6a50
|
| 952 |
f |
f |
|p Can circulate
|a CAVAL
|b CAVAL
|c CAVAL
|d CARM 1 Store
|e C00006
|f A2:AD30E0
|h Other scheme
|i book
|m 0000004
|